Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 8;30(6):5529-5545.
doi: 10.3390/curroncol30060418.

Estimating the Associated Burden of Illness and Healthcare Utilization of Newly Diagnosed Patients Aged ≥65 with Mantle Cell Lymphoma (MCL) in Ontario, Canada

Peter Anglin  1   2 , Julia Elia-Pacitti  3 , Maria Eberg  4 , Sergey Muratov  5 , Atif Kukaswadia  5 , Arushi Sharma  6 , Emmanuel M Ewara  3
Affiliations

Estimating the Associated Burden of Illness and Healthcare Utilization of Newly Diagnosed Patients Aged ≥65 with Mantle Cell Lymphoma (MCL) in Ontario, Canada

Peter Anglin et al. Curr Oncol. .

Abstract

Background: With the emergence of therapies for mantle cell lymphoma (MCL), understanding the treatment patterns and burden of illness among older patients with MCL in Canada is essential to inform decision making.

Methods: A retrospective study using administrative data matched individuals aged ≥65 who were newly diagnosed with MCL between 1 January 2013 and 31 December 2016 with general population controls. Cases were followed for up to 3 years in order to assess healthcare resource utilization (HCRU), healthcare costs, time to next treatment or death (TTNTD), and overall survival (OS); all were stratified according to first-line treatment.

Results: This study matched 159 MCL patients to 636 controls. Direct healthcare costs were highest among MCL patients in the first year following diagnosis (Y1: CAD 77,555 ± 40,789), decreased subsequently (Y2: CAD 40,093 ± 28,720; Y3: CAD 36,059 ± 36,303), and were consistently higher than the costs for controls. The 3-year OS after MCL diagnosis was 68.6%, with patients receiving bendamustine + rituximab (BR) experiencing a significantly higher OS compared to patients treated with other regimens (72.4% vs. 55.6%, p = 0.041). Approximately 40.9% of MCL patients initiated a second-line therapy or died within 3 years.

Conclusion: Newly diagnosed MCL presents a substantial burden to the healthcare system, with almost half of all patients progressing to a second-line therapy or death within 3 years.

Keywords: burden of illness; costs; epidemiology; healthcare utilization; mantle cell lymphoma.

PubMed Disclaimer

Conflict of interest statement

Peter Anglin is a stockholder of Johnson & Johnson. Julia Elia-Pacitti is an employee of Janssen Inc. and a stockholder of Johnson & Johnson. Maria Eberg, Sergey Muratov, Atif Kukaswadia, and Arushi Sharma are employees of IQVIA Solutions Canada Inc. IQVIA is a contract research organization that received consulting fees from Janssen Inc. Emmanuel M. Ewara is an employee of Janssen Inc. and a stockholder of Johnson & Johnson.

Figures

Figure 1
Figure 1
Three-year overall survival for MCL patients. Cumulative incidence function of all-cause mortality for (A) matched MCL patients (n = 159) and (B) matched MCL patients stratified according to LoT. For each time t, patients were considered “at risk” if they had not had an event of interest before time t and were not censored before or at time t. Number at risk was evaluated on day 365 for year 1, day 730 for year 2, and day 1095 for year 3. Shaded regions represent 95% confidence interval (CI).
Figure 2
Figure 2
Time to next therapy or death for MCL patients. Cumulative incidence function of TTNTD for (A) matched MCL patients (n = 159) and (B) matched MCL patients stratified by LoT. For each time t, patients were considered “at risk” if they had not had an event of interest before time t and were not censored before or at time t. Number at risk was evaluated on day 365 for year 1, day 730 for year 2, and day 1095 for year 3. Shaded regions represent 95% confidence interval (CI).
See this image and copyright information in PMC

References

    1. Sapkota S., Shaikh H. StatPearls. StatPearls Publishing; Treasure Island, FL, USA: 2022. Non-Hodgkin Lymphoma. - PubMed
    1. Candian Cancer Society Mantle Cell Lymphoma. [(accessed on 7 November 2022)]. Available online: https://cancer.ca/en/cancer-information/cancer-types/non-hodgkin-lymphom....
    1. Ibrutinib for Mantle Cell Lymphoma (Final Clinical Guidance Report) [(accessed on 4 October 2022)]. Available online: https://www.cadth.ca/sites/default/files/pcodr/pcodr_ibrutinib_imbruvica....
    1. McKay P., Leach M., Jackson B., Robinson S., Rule S. Guideline for the Management of Mantle Cell Lymphoma. Br. J. Haematol. 2018;182:46–62. doi: 10.1111/bjh.15283. - DOI - PubMed
    1. Xin W. A Multi-Center, Prospective Clinical Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Patients With Newly-Diagnosed Aggressive B-Cell Non-Hodgkin Lymphoma. [(accessed on 28 September 2022)];2021 Available online: https://clinicaltrials.gov.

Publication types